INS and type 1 diabetes mellitus: While use of DC antigen-specific therapies in clinic has only recently been explored for T1D one study found that proinsulin pulsed tolerogenic DCs injected intradermally did not affect HbA1c, C peptide, hypoglycemic events or insulin dose required for symptom maintenance (283).